TY  - JOUR
AU  - Lwin, Min Wai
AU  - Schoffer, Olaf
AU  - Streissnig, Christoph
AU  - Wimberger, Pauline
AU  - Gerken, Michael
AU  - Bierbaum, Veronika
AU  - Bobeth, Christoph
AU  - Rößler, Martin
AU  - Dröge, Patrik
AU  - Ruhnke, Thomas
AU  - Günster, Christian
AU  - Tol, Kees Kleihues-van
AU  - Link, Theresa
AU  - Scharl, Anton
AU  - Sturm-Inwald, Elisabeth C
AU  - Kast, Karin
AU  - Papathemelis, Thomas
AU  - Ortmann, Olaf
AU  - Klinkhammer-Schalke, Monika
AU  - Schmitt, Jochen
AU  - Schlander, Michael
TI  - A cost-effectiveness analysis of breast cancer treatment in certified versus non-certified hospitals in Germany.
JO  - International journal of cancer
VL  - nn
SN  - 0020-7136
CY  - Bognor Regis
PB  - Wiley-Liss
M1  - DKFZ-2026-00548
SP  - nn
PY  - 2026
N1  - #EA:C100#LA:C100# / epub
AB  - In Germany, the German Cancer Society (Deutsche Krebsgesellschaft [DKG]) accredits hospitals to ensure high-quality cancer treatment through adherence to clinical guidelines and a multidisciplinary approach. Evidence suggests certified hospitals (CHs) achieve better clinical outcomes and prognoses than non-certified hospitals (NCHs). However, additional services required for certification incur substantial, unreimbursed costs, necessitating a focused cost-effectiveness evaluation. This retrospective cohort study utilized anonymized administrative routine healthcare data from Allgemeine Ortskrankenkasse, Germany's largest statutory health insurance. The study sample comprised 143,720 incident breast cancer (BC) patients treated between 2009 and 2017 across both CHs and NCHs. A health system perspective was used in this cost-effectiveness analysis. Direct medical costs (inpatient, outpatient, medication, and certification) were compared between CHs and NCHs. Life-years gained (LYG) were calculated from 5-year restricted mean survival time. The incremental cost-effectiveness ratio (ICER), quantified as cost per LYG, served as the primary outcome measure, reported in 2024 euro. Treatment in CHs significantly improved breast cancer survival, yielding 201 LYG per 1000 patients (95
KW  - breast cancer (Other)
KW  - breast cancer treatment cost (Other)
KW  - cancer center certification (Other)
KW  - certified hospitals (Other)
KW  - cost‐effectiveness analysis (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41802986
DO  - DOI:10.1002/ijc.70388
UR  - https://inrepo02.dkfz.de/record/310348
ER  -